AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. - 10. (Canceled)

11. (Currently amended) A compound of formula I



I

wherein one of R^1 and R^2 is chosen from

~~$(C_1$-$C_8)$-alkyl which is substituted by at least one identical or different substituents chosen from hydroxy, $(C_1$-$C_4)$-alkyl-$S(O)_m$-, $(C_3$-$C_7)$-cycloalkyl, naphthyl, and pyridyl,~~

unsubstituted $(C_3$-$C_9)$-cycloalkyl, and $(C_3$-$C_9)$-cycloalkyl which is substituted by at least one identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, benzyl, hydroxy, amino, H-CO-O-, $(C_1$-$C_4)$-alkyl-CO-O-, $(C_1$-$C_4)$-alkyl-O-CO-O-, H-CO-NH-, $(C_1$-$C_4)$-alkyl-CO-NH-, $(C_1$-$C_4)$-alkyl-O-CO-NH-, phenyl-CO-NH-, $(C_1$-$C_4)$-alkyl-SO_2-NH-, and phenyl-SO_2-NH-,

and the other of R^1 and R^2 is hydrogen,

wherein phenyl groups, naphthyl groups, pyridyl groups and benzyl groups present in R^1 and R^2 are unsubstituted or substituted on the aromatic ring by at least one identical or different substituents chosen from halogen, $(C_1$-$C_4)$-alkyl, phenyl CF_3, NO_2, OH, -O-$(C_1$-$C_4)$-alkyl, -O-$(C_2$-$C_4)$-alkyl-O-$(C_1$-$C_4)$-alkyl, $(C_1$-$C_2)$-alkylenedioxy, NH_2, -NH-$(C_1$-$C_4)$-alkyl, -N$((C_1$-$C_4)$-alkyl$)_2$, -NH-CHO-, -NH-CO-$(C_1$-$C_4)$-alkyl, -CN, -CO-NH_2,

-CO-NH-(C_1-C_4)-alkyl, -CO-N((C_1-C_4)-alkyl)$_2$, -CO-OH, -CO-O-(C_1-C_4)-alkyl, -CHO and -CO-(C_1-C_4)-alkyl;

wherein R^3 is aryl but cannot be unsubstituted phenyl;

wherein aryl is chosen from unsubstituted napthyl and phenyl, naphthyl and heteroaryl, all of which are unsubstituted or substituted by at least one identical or different substituents chosen from halogen, (C_1-C_4)-alkyl, phenyl, CF_3, NO_2, OH, -O-(C_1-C_4)-alkyl, -O-(C_2-C_4)-alkyl-O-(C_1-C_4)-alkyl, (C_1-C_2)-alkylenedioxy, NH_2, -NH-(C_1-C_4)-alkyl, -N((C_1-C_4)-alkyl)$_2$, -NH-CHO, -NH-CO-(C_1-C_4)-alkyl, -CN, -CO-NH_2, -CO-NH-(C_1-C_4)-alkyl, -CO-N((C_1-C_4)-alkyl)$_2$, -CO-OH, -CO-O-(C_1-C_4)-alkyl, -CHO and -CO-(C_1-C_4)-alkyl;

wherein heteroaryl is chosen from a radical of a monocyclic 5-membered aromatic heterocycle, a radical of a monocyclic 6-membered aromatic heterocycle, a radical of a bicyclic 8-membered aromatic heterocycle, a radical of a bicyclic 9-membered aromatic heterocycle, and a radical of a bicyclic 10-membered aromatic heterocycle, each of which contain at least one identical or different ring heteroatoms chosen from N, O and S; and

wherein m is 0, 1 or 2;

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

12. (Previously presented) The compound as claimed in claim 11, wherein one of R^1 and R^2 is unsubstituted (C_3-C_9)-cycloalkyl or (C_3-C_9)-cycloalkyl which is substituted by at least one identical or different substituents chosen from (C_1-C_4)-alkyl,

hydroxyl, amino, H-CO-O-, (C_1-C_4)-alkyl-CO-O-, (C_1-C_4)-alkyl-O-CO-O-, H-CO-NH-, (C_1-C_4)-alkyl-CO-NH-, (C_1-C_4)-alkyl-O-CO-NH-, phenyl-CO-NH-, (C_1-C_4)-alkyl-SO_2-NH- and phenyl-SO_2-NH-, wherein phenyl groups present in R^1 and R^2 are unsubstituted or substituted,

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

13. (Previously presented) The compound as claimed in claim 11, wherein one of R^1 and R^2 is unsubstituted (C_3-C_9)-cycloalkyl or substituted (C_3-C_9)-cycloalkyl which is substituted by at least one identical or different substituents chosen from (C_1-C_4)-alkyl, hydroxy, amino, (C_1-C_4)-alkyl-CO-O-, (C_1-C_4)-alkyl-CO-NH-, (C_1-C_4)-alkyl-O-CO-NH-, phenyl-CO-NH-, (C_1-C_4)-alkyl-SO_2-NH- and phenyl SO_2-NH-, wherein phenyl groups present in R^1 and R^2 are unsubstituted or substituted, in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

14. (Previously presented) The compound as claimed in claim 11, wherein one of R^1 and R^2 is unsubstituted (C_3-C_9)-cycloalkyl or substituted (C_3-C_9)-cycloalkyl which is substituted by one or two identical or different substituents chosen from (C_1-C_4)-alkyl, hydroxy, amino, H-CO-O-, (C_1-C_4)-alkyl-CO-O-, (C_1-C_4)-alkyl-O-CO-O-, H-CO-NH-, (C_1-C_4)-alkyl-CO-NH-, (C_1-C_4)-alkyl-O-CO-NH-, phenyl-CO-NH-, (C_1-C_4)-alkyl-SO_2-NH- and phenyl SO_2-NH-, wherein phenyl groups present in R^1 and R^2 are unsubstituted or substituted,

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

15. (Previously presented) The compound as claimed in claim 11, wherein one of R^1 and R^2 is cyclopentyl or cyclohexyl each of which are unsubstituted or substituted by at least one identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxy, amino, $(C_1$-$C_4)$-alkyl-CO-O-, $(C_1$-$C_4)$-alkyl-CO-NH-, $(C_1$-$C_4)$-alkyl-O-CO-NH-, phenyl-CO-NH-, $(C_1$-$C_4)$-alkyl-SO_2-NH- and phenyl-SO_2-NH-, wherein phenyl groups present in R^1 and R^2 are unsubstituted or substituted,

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

16. (Previously presented) The compound as claimed in claim 11, wherein one of R^1 and R^2 is $(C_3$-$C_9)$-cycloalkyl which is substituted by a hydroxy group,

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

17. (Previously presented) The compound as claimed in claim 11, wherein one of R^1 and R^2 is chosen from cyclopentyl substituted by a hydroxy group and cyclohexyl substituted by a hydroxy group,

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

18. (Previously presented) The compound as claimed in claim 11, wherein one of R^1 and R^2 is cyclohexyl which is substituted by a hydroxy group,

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

19. (Previously presented) The compound as claimed in claim 11, wherein one of R^1 and R^2 is 4-hydroxycyclohexyl,

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

20. (Cancel)

21. (Cancel)

22. (Previously presented) The compound as claimed in claim 11, wherein R^3 is a substituted phenyl,

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

23. (Previously presented) The compound as claimed in claim 11, wherein R^3 is a phenyl substituted by one or two substituents chosen from halogen and $(C_1$-$C_4)$-alkyl,

in any stereoisomeric form, or mixtures thereof in any ratio, or their physiologically acceptable salts.

24. (Previously presented) The compound as claimed in claim 11, which is selected from

2-(4-chlorophenyl)-4-cyclopentylamino-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(cis/trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(4-acetyloxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(trans-4-aminocyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(trans-4-acetylaminocyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(trans-4-methanesulfonylamino-cyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(trans-4-(4-chlorophenylsulfonylamino)-cyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(trans-4-ethoxycarbonylamino-cyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(trans-4-benzoylaminocyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-methylphenyl)-4-cyclopentylamino-5,6,7,8-tetrahydroquinazoline,

2-(4-methylphenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-methylphenyl)-4-cyclobutylamino-5,6,7,8-tetrahydroquinazoline,

2-(4-methylphenyl)-4-(4-methylcyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-methylphenyl)-4-cyclononylamino-5,6,7,8-tetrahydroquinazoline,

2-(4-methylphenyl)-4-(2-isopropyl-5-methylcyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-methylphenyl)-4-(trans-2-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-methylphenyl)-4-cyclopropylamino-5,6,7,8-tetrahydroquinazoline,

2-(3,4-dimethoxyphenyl)-4-cyclohexylamino-5,6,7,8-tetrahydroquinazoline,

2-(3,4-dimethoxyphenyl)-4-cyclopentylamino-5,6,7,8-tetrahydroquinazoline,

2-(3,4-dimethoxyphenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3-chlorophenyl)-4-cyclopentylamino-5,6,7,8-tetrahydroquinazoline,

2-(3-chlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-methoxyphenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-methoxyphenyl)-4-cyclopentylamino-5,6,7,8-tetrahydroquinazoline,

2-(4-cyanophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3,5-dichlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3,5-dichlorophenyl)-4-cyclohexylamino-5,6,7,8-tetrahydroquinazoline,

2-(3,4-dichlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3,4-dichlorophenyl)-4-cycloheptylamino-5,6,7,8-tetrahydroquinazoline,

2-(2,4-dichlorophenyl)-4-cyclopentylamino-5,6,7,8-tetrahydroquinazoline,

2-(2,4-dichlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(2-chlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3-bromophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3-bromophenyl)-4-cyclopentylamino-5,6,7,8-tetrahydroquinazoline, and

2-(3,5-difluorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline

or their physiologically acceptable salts.

25. (Previously presented) The compound as claimed in claim 11, which is selected from

2-(4-chlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-chlorophenyl)-4-(cis/trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-methylphenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3,4-dimethoxyphenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3-chlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-methoxyphenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(4-cyanophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3,5-dichlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3,4-dichlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(2,4-dichlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(2-chlorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3-bromophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline,

2-(3,5-difluorophenyl)-4-(trans-4-hydroxycyclohexylamino)-5,6,7,8-tetrahydroquinazoline

or their physiologically acceptable salts.

26. (Cancel)

27. (Currently Amended) A process for the preparation of a compound of formula (I) as claimed in claim 11, comprising activating a 4-hydroxytetrahydroquinazoline of formula IV and then reacting it with an amine of the formula VI,





wherein R^1, R^2 and R^3 have the meanings indicated in claim 11.

28. (Previously presented) A pharmaceutical composition, comprising at least one compound as claimed in claim 11 and a physiologically acceptable carrier.

29. (Currently amended) A method for activating at least one soluble guanylate cyclase in a patient for the treatment of at least one disorder selected from hypertension, stroke, angina pectoris, myocardial infarct, and erectile dysfunction, comprising administering to the patient an effective amount of~~adding~~ at least one compound as claimed in claim 11 ~~to said at least one soluble guanylate cyclase~~.

30. (Previously presented) A method for treating at least one disorder associated with a disturbed cGMP balance, comprising administering an effective amount of at least one compound as claimed in claim 11 to a patient in need thereof, wherein the at least one disorder is selected from hypertension, stroke, angina pectoris, myocardial infarct, and erectile dysfunction.

31. (Previously presented) A method for treating hypertension comprising administering an effective amount of at least one compound as claimed in claim 11 to a patient in need thereof.

32. (Previously presented) A method for treating stroke comprising administering an effective amount of at least one compound as claimed in claim 11 to a patient in need thereof.

33. (Previously presented) A method for treating at least one disorder selected from cardiac insufficiency, pulmonary hypertension, and erectile dysfunction, comprising administering an effective amount of at least one compound as claimed in claim 11 to a patient in need thereof.

34. (Previously presented) A method for treating at least one disorder selected from angina pectoris and myocardial infarct, comprising administering an effective amount of at least one compound as claimed in claim 11 to a patient in need thereof.